Article Text

PDF
▼Humalog - a new insulin analogue
  • Relevant BNF section: 6.1.1.1

Abstract

Insulin lispro (Humalog - Lilly) is a genetically engineered human insulin analogue which the manufacturer claims to allow patients "the convenience of injecting immediately before they eat". It is licensed for the treatment of patients who require insulin therapy for maintenance of normal glucose homeostasis and for the initial stabilisation of diabetes mellitus. Here we review insulin lispro and assess its place in the treatment of patients with diabetes.

Statistics from Altmetric.com

  • Relevant BNF section: 6.1.1.1

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.